109 related articles for article (PubMed ID: 20468087)
1. Antitumor activity and toxicological properties of doxorubicin conjugated to [alpha],[beta]-poly[(2-hydroxyethyl)-L-aspartamide] administered intraperitoneally in mice.
Cheng C; Xue W; Diao H; Xia S; Zuo L; He A; Gao F; Huang Z; Chen J; Zhang J
Anticancer Drugs; 2010 Apr; 21(4):362-71. PubMed ID: 20468087
[TBL] [Abstract][Full Text] [Related]
2. Galactosylated α,β-poly[(2-hydroxyethyl)-L-aspartamide]-bound doxorubicin: improved antitumor activity against hepatocellular carcinoma with reduced hepatotoxicity.
Cheng X; Gao F; Xiang J; Jiang X; Chen J; Zhang J
Anticancer Drugs; 2011 Feb; 22(2):136-47. PubMed ID: 20966743
[TBL] [Abstract][Full Text] [Related]
3. Preparation and antitumor activity of a polymeric derivative of methotrexate.
Zhou G; Cheng X; Wu S; Jiang X; Shi X; Chen J; Zhang J; Zhao J
Am J Med Sci; 2012 Oct; 344(4):294-9. PubMed ID: 22885620
[TBL] [Abstract][Full Text] [Related]
4. (-)-Epigallocatechin-3-gallate alleviates doxorubicin-induced cardiotoxicity in sarcoma 180 tumor-bearing mice.
Yao YF; Liu X; Li WJ; Shi ZW; Yan YX; Wang LF; Chen M; Xie MY
Life Sci; 2017 Jul; 180():151-159. PubMed ID: 27956351
[TBL] [Abstract][Full Text] [Related]
5. Poly(L-aspartamide)-based reduction-sensitive micelles as nanocarriers to improve doxorubicin content in cell nuclei and to enhance antitumor activity.
Cui C; Xue YN; Wu M; Zhang Y; Yu P; Liu L; Zhuo RX; Huang SW
Macromol Biosci; 2013 Aug; 13(8):1036-47. PubMed ID: 23828842
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
7. Polyaspartamide-doxorubicin conjugate as potential prodrug for anticancer therapy.
Di Meo C; Cilurzo F; Licciardi M; Scialabba C; Sabia R; Paolino D; Capitani D; Fresta M; Giammona G; Villani C; Matricardi P
Pharm Res; 2015 May; 32(5):1557-69. PubMed ID: 25366547
[TBL] [Abstract][Full Text] [Related]
8. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
9. Effect of intratumoral injection on the biodistribution and therapeutic potential of novel chemophor EL-modified single-walled nanotube loading doxorubicin.
Liu H; Xu H; Wang Y; He Z; Li S
Drug Dev Ind Pharm; 2012 Sep; 38(9):1031-8. PubMed ID: 22794192
[TBL] [Abstract][Full Text] [Related]
10. ATN-161 Peptide Functionalized Reversibly Cross-Linked Polymersomes Mediate Targeted Doxorubicin Delivery into Melanoma-Bearing C57BL/6 Mice.
Zhang N; Xia Y; Zou Y; Yang W; Zhang J; Zhong Z; Meng F
Mol Pharm; 2017 Aug; 14(8):2538-2547. PubMed ID: 28005375
[TBL] [Abstract][Full Text] [Related]
11. Near infra-red laser mediated photothermal and antitumor efficacy of doxorubicin conjugated gold nanorods with reduced cardiotoxicity in swiss albino mice.
Arunkumar P; Raju B; Vasantharaja R; Vijayaraghavan S; Preetham Kumar B; Jeganathan K; Premkumar K
Nanomedicine; 2015 Aug; 11(6):1435-44. PubMed ID: 25881739
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of mito-TEMPO against doxorubicin cardiotoxicity in mice.
Rocha VC; França LS; de Araújo CF; Ng AM; de Andrade CM; Andrade AC; Santos Ede S; Borges-Silva Mda C; Macambira SG; Noronha-Dutra AA; Pontes-de-Carvalho LC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):659-62. PubMed ID: 26712129
[TBL] [Abstract][Full Text] [Related]
13. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.
Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M
Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252
[TBL] [Abstract][Full Text] [Related]
15. The tumor accumulation and therapeutic efficacy of doxorubicin carried in calcium phosphate-reinforced polymer nanoparticles.
Min KH; Lee HJ; Kim K; Kwon IC; Jeong SY; Lee SC
Biomaterials; 2012 Aug; 33(23):5788-97. PubMed ID: 22591612
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
[TBL] [Abstract][Full Text] [Related]
17. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
19. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
20. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
